Biogen Inc. ( (BIIB) ) has released its Q2 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. is a leading biotechnology company focused on developing innovative therapies for neurological and rare diseases, leveraging its deep understanding of human biology to deliver transformative medicines.
In the second quarter of 2025, Biogen reported strong financial results, with total revenue reaching $2.6 billion, marking a 7% increase year-over-year. The company also raised its full-year guidance, reflecting a positive business outlook.
Key financial highlights include a GAAP diluted EPS of $4.33, up 8% from the previous year, and a Non-GAAP diluted EPS of $5.47, up 4%. The company saw significant growth in its Alzheimer’s, rare disease, and postpartum depression product lines, with notable sales increases for LEQEMBI and SKYCLARYS. Biogen also advanced its late-stage pipeline, with several Phase 3 studies initiated.
Looking forward, Biogen has increased its full-year 2025 guidance, expecting Non-GAAP diluted EPS to range between $15.50 and $16.00, and total revenue to remain approximately flat compared to 2024. The company remains focused on expanding its product portfolio and advancing its pipeline for sustainable growth.